Physicians' Academy for Cardiovascular Education

Atherosclerosis

Welcome to the EAS 2022 congress

3' education - May 24, 2022 - Prof. Kausik Ray, MD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD

Immunity and inflammation in atherosclerosis - no longer just a theory

10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD

Panel discussion: Measuring inflammation in the coronary circulation

15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

CVD risk associated with LDL-c is sex specific

Literature - July 4, 2022 - Cupido AJ, et al. - J Am Heart Assoc. 2022

The causal effect of LDL-c on CVD risk was stronger in male than in female participants of the UK Biobank cohort, suggesting that LDL‐c is a less important predictor of CVD risk in women than in men.

E-learning Inflammation: The next therapeutic frontier in targeting cardiovascular risk

Accredited e-Learning

Online-CME - This course consists of 4 parts.
This course consists of 4 parts.

"There are 3 patients with residual inflammatory risk for every patient with residual cholesterol risk," says prof. Ridker. Learn how perspectives on inflammation in atherosclerosis have changed from the1970s up until now and how (novel) anti-inflammatory therapies may reduce CVD risk.

Welcome to the EAS 2022 congress

3' education - May 24, 2022 - Prof. Kausik Ray, MD
Prof. Kausik Ray, the president of the EAS, reflects on the EAS congress, now that participants are onsite again after 2 years.

EAS 2022 Prof. Kausik Ray, the president of the EAS, reflects on the EAS congress, now that participants are onsite again after 2 years.

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.

ACC 2022 ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD
Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Immunity and inflammation in atherosclerosis - no longer just a theory

10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD
Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

Proteomic risk model superior to clinical risk model in predicting recurrent ASCVD events

Literature - Mar. 9, 2022 - Nurmohamed NS et al. - Eur Heart J. 2022

This study investigated the predictive value of a targeted plasma proteomics approach, analyzed with machine learning techniques in a secondary prevention setting.

Elevated Lp(a) associated with adverse plaque progression in ASCVD

Literature - Jan. 26, 2022 - Kaiser Y et al. - J Am Coll Cardiol. 2022

A study shows that elevated Lp(a) is independently associated with accelerated progression of low-attenuation plaque in patients with advanced multivessel CAD on guideline-directed preventive therapies.

Panel discussion: Measuring inflammation in the coronary circulation

15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD
Peter Libby, John Deanfield and Charalambos Antoniades talk about the relevance of coronary inflammation in clinical practice and discuss how inflammation in the coronary circulation can be measured.

Peter Libby, John Deanfield and Charalambos Antoniades talk about the relevance of coronary inflammation in clinical practice and discuss how inflammation in the coronary circulation can be measured.

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD
Charalambos Antoniades explains why coronary inflammation needs to be diagnosed and treated and shows how perivascular fat analysis from routine CTCA can provide a quantitative assessment of coronary inflammation.

Charalambos Antoniades explains why coronary inflammation needs to be diagnosed and treated and shows how perivascular fat analysis from routine CTCA can provide a quantitative assessment of coronary inflammation.

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD
Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Each decade earlier of starting LDL-c lowering associated with stepwise increase in lifetime CV risk reduction

News - Aug. 31, 2021

ESC 2021 The Nature-PCSK9 trial, a naturally randomized target trial, showed a stepwise increase in the proportional reduction in lifetime risk of CV events with each earlier decade that LDL-c lowering was started by inhibiting PCSK9 with one-yearly dose of siRNA.